People are more likely to search for the term "Obamacare" than "Affordable Care Act," but both searches saw spikes in interest following Donald Trump's election, and people are getting curious if the president-elect will keep or repeal the law.
There has always been dual perceptions of the Affordable Care Act (ACA). In 2013, a CBS poll found that people felt differently about the healthcare law depending on what it was called. Nearly half (46%) of the people asked how they felt about Obamacare were opposed to the law compared with just 37% of people who opposed the ACA. Importantly, more people said they didn't know what the ACA was than said the same about Obamacare (30% vs 12%).
It may come as no surprise that the term "Obamacare" has more search interest online than "Affordable Care Act." Regardless, though, both terms saw a spike in search interest following the 2016 presidential election, when Donald Trump's win immediately called into question the future of President Barack Obama's law. Along with increased search interest in both terms, there was a rising interest in people who searched for "Obamacare" also searching for if Trump would keep or repeal the law.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More